Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Genome-wide Association Studies-GWAS

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

Single Nucleotide Polymorphisms-SNPs

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Atp6i deficient mouse model uncovers transforming growth factor-β1 /Smad2/3 as a key signaling pathway regulating odontoblast differentiation and tooth root formation.

International journal of oral science·2023

Same author

Identifiability in Functional Connectivity May Unintentionally Inflate Prediction Results.

ArXiv·2023

Same author

A Mendelian randomization study for drug repurposing reveals bezafibrate and fenofibric acid as potential osteoporosis treatments.

Frontiers in pharmacology·2023

Same author

Identification of potential genetic causal variants for obesity-related traits using statistical fine mapping.

Molecular genetics and genomics : MGG·2023

Same author

ST-V-Net: incorporating shape prior into convolutional neural networks for proximal femur segmentation.

Complex & intelligent systems·2023

Same author

Enteric nervous system damage caused by abnormal intestinal butyrate metabolism may lead to functional constipation.

Frontiers in microbiology·2023

Search research articles

Related Experiment Video

Updated: May 28, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Testing rare variants for association with diseases: a Bayesian marker selection approach.

Lei Zhang¹, Yu-Fang Pei, Rong Hai

¹Center of System Biomedical Sciences, University of Shanghai for Science and Technology, P. R. China.

Annals of Human Genetics

|November 1, 2011

Summary

This study introduces a new Bayesian method for identifying rare genetic variants associated with complex diseases. It improves the power of genetic association studies by weighting variants based on their function and association signals.

More Related Videos

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)

Published on: August 21, 2016

Related Experiment Videos

Last Updated: May 28, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)

Published on: August 21, 2016

Area of Science:

Genetics
Genomic Association Studies
Biostatistics

Background:

Identifying the genetic basis of complex diseases is challenging due to the rarity of causal variants.
Distinguishing rare causal variants from background genomic variation requires effective weighting strategies in association studies.

Purpose of the Study:

To develop a novel Bayesian marker selection approach for weighting-based association tests.
To enhance the identification of rare causal variants in complex disease genetic studies.

Main Methods:

A Bayesian marker selection approach is proposed, utilizing individual association signal and direction for variant weighting.
Predicted biological function of variants is incorporated as prior information to guide the selection of potentially causal variants.

Main Results:

Simulation studies indicate improved statistical power compared to existing methods under specific conditions.
Empirical dataset analyses confirm the practical applicability of the proposed method.

Conclusions:

The novel Bayesian approach effectively weights variants, enhancing the power to detect rare causal mutations.
This method offers a valuable tool for genetic association studies focused on complex diseases.